Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: A prospective cohort study

Internal and Emergency Medicine

Volumn 6, Issue 2, 2011, Pages 117-123

  Angeloni, Giulia ^a,b   Alberti, Silvia ^b   Romagnoli, Enrico ^b   Banzato, Alberto ^c   Formichi, Marco ^d   Cucchini, Umberto ^e   Pengo, Vittorio ^e  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d Civil Hospital   (Italy)

^e UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Atrial fibrillation; Cardioembolism; Electrical cardioversion; Parnaparin

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; PARNAPARIN; VITAMIN K GROUP;

AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG ANTAGONISM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CONFIDENCE INTERVALS; ELECTRIC COUNTERSHOCK; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOEMBOLISM; VITAMIN K;

EID: 79953025433     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0479-1     Document Type: Article

References (32)

1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ (2004) Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 110: 1042-1046.
2. Freestone B, Lip GYH (2003) Epidemiology and costs of cardiac arrhythmias. In: Lip GYH, Godtfredsen J (eds) Cardiac arrhythmias: a clinical approach. Mosby, Edinburgh.
3. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27: 949-953.
4. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 98: 476-484.
5. Wyse DG, Waldo AL, Di Marco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: 1825-1833.
6. van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ, Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347: 1834-1840.
7. Lown B (1967) Electrical reversion of cardiac arrhythmias. Br Heart J 29: 469-489.
8. Gallagher MM, Guo XH, Poloniecki JD, Guan Yap Y, Ward D, Camm AJ (2001) Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 38: 1498-1504.
9. Lown B, Amarasingham R, Neuman J (1962) New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. JAMA 182: 548-555.
10. Berger M, Schweitzer P (1998) Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 82: 1545-1547.
11. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP (1994) Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol 23: 307-316.
12. Black IW, Fatkin D, Sagar KB, Khandheria BK, Leung DY, Galloway JM, Feneley MP, Walsh WF, Grimm RA, Stollberger C (1994) Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 89: 2509-2513.
13. Maltagliati A, Galli CA, Tamborini G, Calligaris A, Doria E, Salehi R, Pepi M (2006) Usefulness of transoesophageal echocardiography before cardioversion in patients with atrial fibrillation and different anticoagulant regimens. Heart 92: 933-938.
14. Dettori AG (1995) Parnaparin: a review of its pharmacological profile and clinical application. Drugs Today 31: 19-35.
15. Zhao L, Zhang Z, Kolm P, Jasper S, Lewis C, Klein A, Weintraub W, ACUTE II Investigators (2008) Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from assessment of cardioversion using transesophageal echocardiography [ACUTE II] randomized multicenter study). Am J Cardiol 101: 338-342.
16. Frampton JE, Faulds D (1994) Parnaparin: a review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs 47: 652-676.
17. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870.
18. Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S, Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA) (2009) Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 119: 2920-2927.
19. Manning WJ, Silvermann DI, Katz SE, Riley MF, Come PC, Doherty RM, Munson JT, Douglas PS (1994) Impaired left atrial function after cardioversion: relationship to the duration of atrial fibrillation. J Am Col Cardiol 23: 1535-1540.
20. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GYH, Mannin WJ (2008) Antithrombotic Therapy in Atrial fibrillation. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 33(6 Suppl.): 546S-592S.
21. Stellbrink C, Hanrath P (2000) The optimal management of cardioversion of atrial fibrillation or flutter: still stunning problem. Eur Heart J 21: 795-798.
22. Yigit Z, Küçükoglu MS, Okçün B, Sansoy V, Güzelsoy D (2003) The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation. Jpn Heart J 44(3): 369-377.
23. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF for the Assessment of Cardioversion Using Transesophageal Echocardiography Investigators (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344: 1411-1420.
24. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA, ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group (2004) Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation. The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Circulation 109: 997-1003.
25. Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG, Hanrath P, Mügge A, Klein HU, Schmidt-Lucke JA (2007) Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thrombosis Res 119: 27-34.
26. Roijer A, Eskilsson J, Olsson B (2000) Transesophageal echocardiography guided cardioversion of atrial fibrillation or flutter. Eur Heart J 21: 837-847.
27. Murray RD, Shah A, Jasper SE, Goodman A, Deitcher SR, Katz WE, Malouf JF, Stoddard MF, Grimm RA, Klein AL, ACUTE II pilot study (2000) Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study. Am Heart J 139: 1-7.
28. Klein AL, Jasper SE, Katz WE, Malouf JF, Pape LA, Stoddard MF, Apperson-Hansen C, Lieber EA, ACUTE II Steering and Publications Committee for the ACUTE II Investigators (2006) The use of enoxaparin compared with unfractionated heparin for short- term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J 27: 2858-2865.
29. Elliott DJ, Zhao L, Jasper SE, Lieber EA, Klein AL, Weintraub WS (2008) Health status outcomes after cardioversion for atrial fibrillation: results from the assessment of cardioversion using transesophageal echocardiography (ACUTE) II trial. Am Heart J 156: 1-6.
30. De Luca I, Sorino M, De Luca L, Colonna P, Del Salvatore B, Corlianò L (2005) Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up. Int J Cardiol 102: 447-454.
31. McKeage K, Keating GM (2008) Parnaparin: a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs 68: 105-122.
32. Camporese G, Bernardi E, Noventa F (2009) Update on the clinical use of the low-molecular-weight heparin, parnaparin. Vasc Health Risk Manag 5: 819-831.